Regeneron Pharmaceuticals Forecast, price target & analysts
Regeneron Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Regeneron Pharmaceuticals Classifications & Recommendation
Regeneron Pharmaceuticals Price Target
| Target Price | $882.30 |
| Price | $816.10 |
| Potential | 8.11% |
| Number of Estimates | 32 |
| 32 Analysts have issued a price target Regeneron Pharmaceuticals 2027 . The average Regeneron Pharmaceuticals target price is $882.30. This is 8.11% higher than the current stock price. The highest price target is $1,081.50 32.52% , the lowest is $744.37 8.79% . | |
| A rating was issued by 38 analysts: 26 Analysts recommend Regeneron Pharmaceuticals to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2027 of 8.11% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
32 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
14 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2026. The average Regeneron Pharmaceuticals EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
33 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Regeneron Pharmaceuticals net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
33 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
Regeneron Pharmaceuticals...
Current Regeneron Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD Cowen |
Buy
➜
Buy
|
Unchanged | Oct 21 2026 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Oct 19 2026 |
| UBS |
Neutral
➜
Buy
|
Upgrade | Oct 15 2026 |
| RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Oct 08 2026 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Oct 07 2026 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 07 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Oct 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
TD Cowen:
Buy
➜
Buy
|
Oct 21 2026 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Oct 19 2026 |
|
Upgrade
UBS:
Neutral
➜
Buy
|
Oct 15 2026 |
|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Oct 08 2026 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Oct 07 2026 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Oct 07 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Oct 06 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
